MACSF

COMMUNIQUÉS West-GlobeNewswire

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
24/06/2025
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing [...]
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
24/06/2025
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE [...]
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
24/06/2025
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities
24/06/2025
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has [...]
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
24/06/2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel [...]
InnovAge PACE Sponsors Documentary Spotlighting National Crisis in Family Caregiving
24/06/2025
PBS “Caregiving” Documentary, featuring Actor Bradley Cooper, Premieres Tonight DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- InnovAge, the nation’s largest provider of the Program of All-inclusive Care for the Elderly ( [...]
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
24/06/2025
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader [...]
Pioneering New Study Finds Most U.S. Babies Lack Key Gut Bacteria, Increasing Risk for Allergies and Other Chronic Health Issues
24/06/2025
Initial findings published today in Communications Biology - a Nature portfolio journal - show that 76% of infants in the U.S. are deficient in Bifidobacterium, a gut microbiome genus responsible for the utilization of [...]
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
24/06/2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
24/06/2025
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to [...]
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight
24/06/2025
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss. No treatment-related [...]
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
24/06/2025
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, [...]
Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)
24/06/2025
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, [...]
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
24/06/2025
First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatments Partnership aims to improve survival and [...]
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
24/06/2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]
Solésence to Join Russell 3000® and Russell 2000® Indexes
24/06/2025
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be [...]
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
24/06/2025
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by [...]
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
24/06/2025
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell [...]
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
24/06/2025
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC HOUSTON, [...]

Pages